Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer
Not Applicable
Completed
- Conditions
- Endometrial Cancer
- Registration Number
- NCT00482300
- Lead Sponsor
- University of Roma La Sapienza
- Brief Summary
The purpose of this trial is to determine whether the addition of systematic pelvic lymphadenectomy to hysterectomy with bilateral adnexectomy improves disease-free survival (DFS) and overall survival (OS) in patients with preoperatively supposed Stage I-II endometrial cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Histologically proven endometrioid or adenosquamous endometrial carcinoma.
- Patients having myometrial invasion
- Age =/< 75 years
- Informed consent.
Exclusion Criteria
- Serous papillary and clear cell tumors.
- Karnofsky index < 80 or severe diseases contraindicating surgery
- Concomitant neoplasia (basalioma cutis excluded)
- Distant metastasis or abdominal metastasis detected intraoperatively.
- Absence of myometrial invasion at frozen section.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the impact of systematic pelvic lymphadenectomy on DFS and OS in Stage I-II endometrial cancer patients?
How does systematic pelvic lymphadenectomy compare to standard hysterectomy in managing endometrial cancer recurrence?
Are there specific biomarkers that predict survival outcomes following lymphadenectomy in endometrial cancer?
What are the potential adverse events associated with systematic pelvic lymphadenectomy in cancer treatment?
What molecular pathways are influenced by lymph node dissection in endometrial cancer progression?